Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb

Patent expirations impact results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb
 
2Q Revenues: $4.4 billion (-18%)

2Q Earnings: $808 million (-38%)

YTD Revenues: $9.7 billion (-7%)

YTD Earnings: $2.3 billion (-14%)

Comments: U.S. sales were down 27% to $2.6 billion in the quarter due to patent expirations for Avapro/Avalide (-40%) and Plavix (-33%). Abilify sales were $711 million (+1%). Reyataz sales were $406 million (+3%). Sustiva Franchise sales were $388 million (+5%). Onglyza/Kombiglyze sales were up 54% to $174 million, Baraclude sales were up 22% to $357 million, Orencia sales were up 27% to $290 million, Sprycel sales were up 26% to $244 million and Yervoy sales were $162 million (+71%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters